BioTuesdays

Author - Melane Sampson

Clovis Oncology Logo

Leerink cuts Clovis Oncology PT to $22 from $30

Leerink lowered its price target for Clovis Oncology (NASDAQ:CLVS) to $22 from $30 but maintained its “market perform” rating after the company reported third quarter results. The stock closed at $16.61 on Oct. 30...

Immune Design

Leerink cuts Immune Design to MP; PT to $3 from $7

Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.